Assessing possible long-term effects is particularly relevant, as there are concerns about PCSK9 inhibitors exhibiting adverse neurocognitive effects as well as increasing the risk of type 2 diabetes and cancer [41–43]. The gene discussed is PCSK9; the disease is type 2 diabetes mellitus.